Odeh Hana, Miranda Lisa, Rao Abhi, Vaught Jim, Greenman Howard, McLean Jeffrey, Reed Daniel, Memon Sarfraz, Fombonne Benjamin, Guan Ping, Moore Helen M
1 National Cancer Institute , Biorepositories and Biospecimen Research Branch (BBRB), Bethesda, Maryland.
2 Kelly Government Solutions , Rockville, Maryland.
Biopreserv Biobank. 2015 Dec;13(6):421-9. doi: 10.1089/bio.2015.0089.
Biospecimens are essential resources for advancing basic and translational research. However, there are little data available regarding the costs associated with operating a biobank, and few resources to enable their long-term sustainability. To support the research community in this effort, the National Institutes of Health, National Cancer Institute's Biorepositories and Biospecimen Research Branch has developed the Biobank Economic Modeling Tool (BEMT). The tool is accessible at http://biospecimens.cancer.gov/resources/bemt.asp.
To obtain market-based cost information and to inform the development of the tool, a survey was designed and sent to 423 biobank managers and directors across the world. The survey contained questions regarding infrastructure investments, salary costs, funding options, types of biospecimen resources and services offered, as well as biospecimen pricing and service-related costs.
A total of 106 responses were received. The data were anonymized, aggregated, and used to create a comprehensive database of cost and pricing information that was integrated into the web-based tool, the BEMT. The BEMT was built to allow the user to input cost and pricing data through a seven-step process to build a cost profile for their biobank, define direct and indirect costs, determine cost recovery fees, perform financial forecasting, and query the anonymized survey data from comparable biobanks.
A survey was conducted to obtain a greater understanding of the costs involved in operating a biobank. The anonymized survey data was then used to develop the BEMT, a cost modeling tool for biobanks. Users of the tool will be able to create a cost profile for their biobanks' specimens, products and services, establish pricing, and allocate costs for biospecimens based on percent cost recovered, and perform project-specific cost analyses and financial forecasting.
生物样本是推进基础研究和转化研究的重要资源。然而,关于生物样本库运营成本的数据很少,且几乎没有资源来确保其长期可持续性。为了在这方面支持研究界,美国国立卫生研究院国家癌症研究所的生物样本库与生物样本研究分支开发了生物样本库经济建模工具(BEMT)。该工具可在http://biospecimens.cancer.gov/resources/bemt.asp上获取。
为了获取基于市场的成本信息并为工具的开发提供参考,设计了一项调查并发送给全球423位生物样本库经理和主任。该调查包含有关基础设施投资、薪资成本、资金选择、提供的生物样本资源和服务类型,以及生物样本定价和服务相关成本的问题。
共收到106份回复。数据经过匿名处理、汇总,并用于创建一个综合的成本和定价信息数据库,该数据库已集成到基于网络的工具BEMT中。BEMT的构建旨在允许用户通过一个七步流程输入成本和定价数据,以构建其生物样本库的成本概况,定义直接和间接成本,确定成本回收费用,进行财务预测,并查询来自可比生物样本库的匿名调查数据。
进行了一项调查,以更深入地了解生物样本库运营所涉及的成本。然后,利用匿名调查数据开发了BEMT,这是一种用于生物样本库的成本建模工具。该工具的用户将能够为其生物样本库的样本、产品和服务创建成本概况,确定定价,并根据成本回收百分比分配生物样本的成本,以及进行特定项目的成本分析和财务预测。